{
    "clinical_study": {
        "@rank": "133047", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see whether an HIV vaccine, ALVAC vCP205, is safe and can\n      prevent HIV infection. The vCP205 vaccine will be tested with another vaccine,\n      gp160MN/LAI-2."
        }, 
        "brief_title": "A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection", 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study consists of 2 parts:\n\n      Part A: Dose-escalation protocol using oligomeric gp160MN/LAI-2. Part B: Placebo-controlled,\n      randomized, double-blind (within arm) study of vCP205 priming with gp160MN/LAI-2 boosting.\n\n      Volunteers are followed for at least 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Volunteers may be eligible for this study if they:\n\n          -  Are HIV-negative.\n\n          -  Are in good health.\n\n          -  Are between ages 18 and 55.\n\n          -  Are available for at least 1 year.\n\n          -  Are a resident of the United States of America.\n\n          -  Agree to practice sexual abstinence or use birth control.\n\n        Exclusion Criteria\n\n        Volunteers will not be eligible for this study if they:\n\n          -  Have ever been given an HIV vaccine or certain other vaccines. (However, rabies\n             vaccines are allowed.)\n\n          -  Participate in activities that place them at high-risk for HIV infection, such as\n             injection drug use or unprotected sex with someone who has HIV infection.\n\n          -  Have certain psychiatric, medical, or substance abuse problems.\n\n          -  Are allergic to eggs or other vaccines.\n\n          -  Are an employee at a participating site and have access to study information.\n\n          -  Are taking certain medications.\n\n          -  Have received blood transfusions within 3 months before entering this study.\n\n          -  Are pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004579", 
            "org_study_id": "RV124"
        }, 
        "intervention": [
            {
                "intervention_name": "gp160 MN/LAI-2", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "ALVAC-HIV MN120TMG (vCP205)", 
                "intervention_type": "Biological"
            }
        ], 
        "keyword": [
            "Vaccines, Synthetic", 
            "Viral Vaccines", 
            "HIV-1", 
            "Dose-Response Relationship, Drug", 
            "HIV Envelope Protein gp160", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "Avipoxvirus", 
            "Immunization", 
            "HIV Envelope Protein gp120", 
            "Recombination, Genetic"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rockville", 
                    "country": "United States", 
                    "state": "Maryland"
                }, 
                "name": "Walter Reed Army Institute of Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults", 
        "overall_official": {
            "last_name": "Jerome H. Kim", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Kim J, Robb M, Cox J, Ratto-Kim S, Vancott T, Zahwa H, Malia J, Chaddic C, El Habib R, Caudrelier P, Klein M, Excler JL, Birx D, McNeil J. Humoral and cellular HIV-specific responses induced by the prime-boost combination of Aventis-Pasteur ALVAC-HIV (vCP205) and oligomeric HIV-1 gp160MN/LAI-2 in HIV-uninfected adults. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 179)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004579"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Walter Reed Army Institute of Research (WRAIR)", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "April 1998", 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2003"
    }, 
    "geocoordinates": {
        "Walter Reed Army Institute of Research": "39.084 -77.153"
    }
}